KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 2, 2009, Pages 603-608

  Aaboe, Kasper ^a,b   Knop, Filip Krag ^a   Vilsboll, Tina ^a   Vølund, Aage ^d   Simonsen, Ulf ^c   Deacon, Carolyn Fiona ^b   Madsbad, Sten ^a   Holst, Jens Juul ^b   Krarup, Thure ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM); C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLIPIZIDE; GLUCAGON; GLUCOSE; INCRETIN; INSULIN; METFORMIN; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT RESPONSE; BLOOD; CHANNEL GATING; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; GLUCOSE CLAMP TECHNIQUE; INFUSION PUMP; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

MUS;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INFUSION PUMPS; INSULIN; INSULIN RESISTANCE; ION CHANNEL GATING; KATP CHANNELS; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 59749096702     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1731     Document Type: Article

References (34)

1. Nauck M, Stockmann F, Ebert R, Creutzfeldt W 1986 Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46-52
2. Kjems LL, Holst JJ, Volund A, Madsbad S 2003 The influence of GLP-1 on glucose-stimulated insulin secretion. Effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380-386
3. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ 2001 Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717-3723
4. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ 2001 Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613
5. Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK 1994 The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 51:63-74
6. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W 1993 Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307
7. Sale MM, Rich SS 2007 Genetic contributions to type 2 diabetes: recent insights. Expert Rev Mol Diagn 7:207-217
8. Miki T, Minami K, Shinozaki H, Matsumura K, Saraya A, Ikeda H, Yamada Y, Holst JJ, Seino S 2005 Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. Diabetes 54:1056-1063
9. Shiota C, Larsson O, Shelton KD, Shiota M, Efanov AM, Hoy M, Lindner J, Kooptiwut S, Juntti-Berggren L, Gromada J, Berggren PO, Magnuson MA 2002 Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose. J Biol Chem 277:37176-37183
10. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Molnes J, Edghill EL, Frayling TM, Temple IK, Mackay D, Shield JP, Sumnik Z, van Rhijn A, Wales JK, Clark P, Gorman S, Aisenberg J, Ellard S, Njolstad PR, Ashcroft FM, Hattersley AT 2004 Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 350:1838-1849
11. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Sovik O, Polak M, Hattersley AT 2006 Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355:467-477
12. Meneilly GS, Bryer-Ash M, Elahi D 1993 The effect of glyburide on β-cell sensitivity to glucose-dependent insulinotropic polypeptide. Diabetes Care 16:110-114
13. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ 2000 Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575-3581
14. Orskov C, Jeppesen J, Madsbad S, Holst JJ 1991 Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87:415-423
15. Baldissera FGA, Holst JJ 1984 Glucagon-related peptides in the human gastrointestinal mucosa. Diabetologia 26:223-228
16. Holst JJ, Pedersen JH, Baldissera F, Stadil F 1983 Circulating glucagon after total pancreatectomy in man. Diabetologia 25:396-399
17. Kjems LL, Christiansen E, Volund A, Bergman RN, Madsbad S 2000 Validation of methods for measurement of insulin secretion in humans in vivo. Diabetes 49:580-588
18. Aburuz S, Millership J, McElnay J 2005 The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide or glimperide in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 817:277-286
19. Paroni R, Comuzzi B, Arcelloni C, Brocco S, de Kreutzenberg S, Tiengo A, Ciucci A, Beck-Peccoz P, Genovese S 2000 Comparison of capillary electrophoresis with HPLC for diagnosis of factitious hypoglycemia. Clin Chem 46:1773-1780
20. Kjems LL, Volund A, Madsbad S 2001 Quantification of β-cell function during IVGTT in type II and non-diabetic subjects: assessment of insulin secretion by mathematical methods. Diabetologia 44:1339-1348
21. Van Cauter E, Mestrez F, Sturis J, Polonsky KS 1992 Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368-377
22. Vilsboll T, Agerso H, Lauritsen T, Deacon CF, Aaboe K, Madsbad S, Krarup T, Holst JJ 2006 The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regul Pept 137:168-172
23. Vilsboll T, Krarup T, Madsbad S, Holst JJ 2002 Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45:1111-1119
24. Xu G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedi N, Suzuma K, King GL, Weir GC, Bonner-Weir S 2007 Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 56:1551-1558
25. Lynn FC, Thompson SA, Pospisilik JA, Ehses JA, Hinke SA, Pamir N, McIntosh CH, Pederson RA 2003 A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in β cells. FASEB J 17:91-93
26. Schmid-Antomarchi H, De Weille J, Fosset M, Lazdunski M 1987 The receptor for antidiabetic sulfonylureas controls the activity of the ATP-modulated K+ channel in insulin-secreting cells. J Biol Chem 262:15840-15844
27. Polonsky KS, Rubenstein AH 1984 C-Peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes 33:486-494
28. Brunzell JD, Robertson RP, Lerner RL, Hazzard WR, Ensinck JW, Bierman EL, Porte Jr D 1976 Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 42:222-229
29. Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE, Nauck MA 2003 Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46:798-801
30. Gopel SO, Kanno T, Barg S, Weng XG, Gromada J, Rorsman P 2000 Regulation of glucagon release in mouse cells by KATP channels and inactivation of TTX-sensitive Na+ channels. J Physiol 528:509-520
31. Grodsky GM, Epstein GH, Fanska R, Karam JH 1977 Pancreatic action of the sulfonylureas. Fed Proc 36:2714-2719
32. Kadowaki S, Taminato T, Chiba T, Nozawa M, Fujita T, Norman AW 1983 Effect of tolbutamide on insulin, glucagon, and somatostatin release from the diabetic rat pancreas with special reference to glucose concentration. Endocrinology 112:2187-2192
33. Meier JJ, Gallwitz B, Kask B, Deacon CF, Holst JJ, Schmidt WE, Nauck MA 2004 Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes 53(Suppl 3):S220-S224
34. Hojberg PV, Vilsbol T, Knop FK, Bache M, Madsbad S, Krarup T, Holst JJ 2007 Four weeks of near-normalization of blood glucose restores the insulin response to GIP and improves the insulin response to GLP-1 in patients with type 2 diabetes. Diabetes 56:A373